JP2018521064A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521064A5 JP2018521064A5 JP2018500373A JP2018500373A JP2018521064A5 JP 2018521064 A5 JP2018521064 A5 JP 2018521064A5 JP 2018500373 A JP2018500373 A JP 2018500373A JP 2018500373 A JP2018500373 A JP 2018500373A JP 2018521064 A5 JP2018521064 A5 JP 2018521064A5
- Authority
- JP
- Japan
- Prior art keywords
- her2
- kit
- her2 antibody
- cancer
- bcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021112329A JP2021178825A (ja) | 2015-07-07 | 2021-07-06 | 抗ｈｅｒ２抗体−薬物複合体とｂｃｌ−２阻害剤の併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189610P | 2015-07-07 | 2015-07-07 | |
| US62/189,610 | 2015-07-07 | ||
| PCT/US2016/041184 WO2017007846A1 (en) | 2015-07-07 | 2016-07-06 | Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112329A Division JP2021178825A (ja) | 2015-07-07 | 2021-07-06 | 抗ｈｅｒ２抗体−薬物複合体とｂｃｌ−２阻害剤の併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521064A JP2018521064A (ja) | 2018-08-02 |
| JP2018521064A5 true JP2018521064A5 (enExample) | 2019-08-08 |
| JP6910339B2 JP6910339B2 (ja) | 2021-07-28 |
Family
ID=56464320
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018500373A Active JP6910339B2 (ja) | 2015-07-07 | 2016-07-06 | 抗ｈｅｒ２抗体−薬物複合体とｂｃｌ−２阻害剤の併用療法 |
| JP2021112329A Pending JP2021178825A (ja) | 2015-07-07 | 2021-07-06 | 抗ｈｅｒ２抗体−薬物複合体とｂｃｌ−２阻害剤の併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112329A Pending JP2021178825A (ja) | 2015-07-07 | 2021-07-06 | 抗ｈｅｒ２抗体−薬物複合体とｂｃｌ−２阻害剤の併用療法 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10898570B2 (enExample) |
| EP (1) | EP3319995B1 (enExample) |
| JP (2) | JP6910339B2 (enExample) |
| KR (2) | KR20240129101A (enExample) |
| CN (2) | CN107922504B (enExample) |
| AU (1) | AU2016290065B2 (enExample) |
| BR (1) | BR112017028012A2 (enExample) |
| CA (1) | CA2990465A1 (enExample) |
| DK (1) | DK3319995T3 (enExample) |
| ES (1) | ES2731377T3 (enExample) |
| HR (1) | HRP20191019T1 (enExample) |
| HU (1) | HUE044139T2 (enExample) |
| IL (1) | IL256451B (enExample) |
| LT (1) | LT3319995T (enExample) |
| MX (1) | MX2018000135A (enExample) |
| PL (1) | PL3319995T3 (enExample) |
| PT (1) | PT3319995T (enExample) |
| RS (1) | RS58823B1 (enExample) |
| SI (1) | SI3319995T1 (enExample) |
| TR (1) | TR201908138T4 (enExample) |
| WO (1) | WO2017007846A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT4241849T (pt) | 2011-10-14 | 2024-10-30 | Hoffmann La Roche | Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo |
| US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
| CN107349426B (zh) * | 2017-07-12 | 2018-03-23 | 马骥 | 阿司匹林与曲妥珠单抗联合或协同在肿瘤治疗中的应用 |
| CN114269749B (zh) | 2019-06-10 | 2024-10-01 | 苏特罗生物制药公司 | 5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物 |
| JP7590354B2 (ja) * | 2019-06-10 | 2024-11-26 | ストロ バイオファーマ インコーポレーテッド | 免疫調節物質抗体薬物コンジュゲートおよびその使用 |
| WO2024211811A2 (en) * | 2023-04-05 | 2024-10-10 | Frezent Biological Solutions, Inc. | Methods and compositions for antibody-drug conjugates |
| CN119454975B (zh) * | 2024-12-02 | 2025-10-21 | 中国医学科学院医学实验动物研究所 | 一种药物组合物在治疗癌症中的应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| BRPI9910332B8 (pt) | 1998-05-06 | 2021-05-25 | Genentech Inc | método para purificação de um polipeptídio a partir de uma composição |
| WO1999060023A1 (en) | 1998-05-15 | 1999-11-25 | Imclone Systems Incorporated | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
| BRPI0012196B8 (pt) * | 1999-06-25 | 2021-05-25 | Genentech Inc | artigo industrializado |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| CN1447696A (zh) * | 2000-05-19 | 2003-10-08 | 杰南技术公司 | 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
| US7795232B1 (en) | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6790954B2 (en) | 2002-01-29 | 2004-09-14 | Immunogen, Inc. | Mutant Actinosynnema pretiosum strain with increased maytansinoid production |
| WO2004056971A2 (en) * | 2002-12-19 | 2004-07-08 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| US7432088B2 (en) | 2003-05-08 | 2008-10-07 | Immunogen Inc. | Methods for the production of ansamitocins |
| US7004206B2 (en) | 2004-01-29 | 2006-02-28 | Viken James P | Automatic fluid exchanger |
| MXPA06014065A (es) | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| NZ587706A (en) * | 2008-03-18 | 2012-12-21 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| AU2014240234B2 (en) * | 2008-03-18 | 2016-10-06 | Genentech, Inc. | Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CA2929347A1 (en) | 2009-05-26 | 2010-12-02 | Milan Bruncko | (hetero)aryl substituted sulfonyl-2-(1h-pyrrolo[2,3-b]pyridine-5-oxy)benzamide compounds and their use as apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| AU2011242990B2 (en) * | 2010-04-19 | 2015-02-12 | Biomarker Strategies, Llc. | Compositions and methods for prediction of drug sensitivity, resistance, and disease progression |
| WO2011146568A1 (en) * | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| KR101923364B1 (ko) * | 2010-11-23 | 2018-11-30 | 애브비 인코포레이티드 | 아폽토시스유도제의 염 및 결정형 |
| US20140161827A1 (en) * | 2011-05-09 | 2014-06-12 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
| KR101915942B1 (ko) * | 2012-06-08 | 2018-11-06 | 에프. 호프만-라 로슈 아게 | 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물 |
| MX2015002947A (es) * | 2012-09-07 | 2015-09-23 | Genentech Inc | Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo. |
| CN104370905B (zh) * | 2014-10-22 | 2016-06-01 | 南京友杰医药科技有限公司 | Bcl-2抑制剂ABT-199的合成 |
-
2016
- 2016-07-06 JP JP2018500373A patent/JP6910339B2/ja active Active
- 2016-07-06 HR HRP20191019TT patent/HRP20191019T1/hr unknown
- 2016-07-06 BR BR112017028012-4A patent/BR112017028012A2/en not_active Application Discontinuation
- 2016-07-06 TR TR2019/08138T patent/TR201908138T4/tr unknown
- 2016-07-06 MX MX2018000135A patent/MX2018000135A/es unknown
- 2016-07-06 RS RS20190727A patent/RS58823B1/sr unknown
- 2016-07-06 CN CN201680040184.1A patent/CN107922504B/zh active Active
- 2016-07-06 KR KR1020247027710A patent/KR20240129101A/ko not_active Ceased
- 2016-07-06 ES ES16741212T patent/ES2731377T3/es active Active
- 2016-07-06 PT PT16741212T patent/PT3319995T/pt unknown
- 2016-07-06 CN CN202110774906.9A patent/CN113607945B/zh active Active
- 2016-07-06 SI SI201630278T patent/SI3319995T1/sl unknown
- 2016-07-06 HU HUE16741212A patent/HUE044139T2/hu unknown
- 2016-07-06 EP EP16741212.1A patent/EP3319995B1/en active Active
- 2016-07-06 AU AU2016290065A patent/AU2016290065B2/en active Active
- 2016-07-06 PL PL16741212T patent/PL3319995T3/pl unknown
- 2016-07-06 CA CA2990465A patent/CA2990465A1/en active Pending
- 2016-07-06 DK DK16741212.1T patent/DK3319995T3/da active
- 2016-07-06 WO PCT/US2016/041184 patent/WO2017007846A1/en not_active Ceased
- 2016-07-06 LT LTEP16741212.1T patent/LT3319995T/lt unknown
- 2016-07-06 KR KR1020187000356A patent/KR102697939B1/ko active Active
-
2017
- 2017-12-20 US US15/849,018 patent/US10898570B2/en active Active
- 2017-12-20 IL IL256451A patent/IL256451B/en unknown
-
2020
- 2020-12-21 US US17/129,096 patent/US20210213130A1/en not_active Abandoned
-
2021
- 2021-07-06 JP JP2021112329A patent/JP2021178825A/ja active Pending
-
2024
- 2024-05-09 US US18/659,241 patent/US20240277838A1/en not_active Abandoned
- 2024-12-17 US US18/984,106 patent/US20250121058A1/en active Pending
-
2025
- 2025-08-08 US US19/294,660 patent/US20250367287A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7818502B2 (ja) | 胃腸間質腫瘍を治療するためのリプレチニブ | |
| JP2019031506A (ja) | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 | |
| Liu et al. | Ultrasound-mediated destruction of paclitaxel and oxygen loaded lipid microbubbles for combination therapy in ovarian cancer xenografts | |
| CN113038950A (zh) | 用于治疗神经母细胞瘤的Aurora A激酶抑制剂 | |
| Jia et al. | Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity | |
| JP2014132009A5 (enExample) | ||
| Cho et al. | Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer | |
| KR20160066554A (ko) | 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료 | |
| JP2013227350A (ja) | 放射線直腸ｓ状結腸炎を処置するための組成物および方法 | |
| JP2012500180A5 (enExample) | ||
| JP2023022190A (ja) | 癌治療 | |
| CA3080644A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| JP2019530706A5 (enExample) | ||
| HRP20191019T1 (hr) | Kombinacijska terapija konjugatom protutijela i lijeka anti-her2 i inhibitorom bcl-2 | |
| ES2880444T3 (es) | Combinación de metotrexato y simvastatina para su uso en el tratamiento del osteosarcoma | |
| Chen et al. | ATTRACTION-04 (ONO-4538-37): A randomized, multicenter, phase 2/3 study of nivolumab (Nivo) plus chemotherapy in patients (Pts) with previously untreated advanced or recurrent gastric (G) or gastroesophageal junction (GEJ) cancer | |
| Wen et al. | CTNI-12. Preliminary results of the abemaciclib arm in the individualized screening trial of innovative glioblastoma therapy (INSIGHT): a phase II platform trial using Bayesian adaptive randomization | |
| CN111728974B (zh) | 西奥罗尼用于小细胞肺癌的治疗 | |
| Chen et al. | PACTO: A single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer | |
| JP7696006B2 (ja) | 化膿性汗腺炎の治療における使用のためのレミブルチニブ | |
| JP4982377B2 (ja) | 過剰増殖性疾病の治療及び予防のための組成物及び方法 | |
| JP7372740B2 (ja) | 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ | |
| TW201306833A (zh) | 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合 | |
| CN114929246A (zh) | 碘化物化合物用于治疗和预防化学疗法相关的恶病质和心脏毒性的用途 | |
| Yilmaz et al. | The validity and reliability of the trypophobia questionnaire Turkish form |